Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317863042> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4317863042 endingPage "TPS485" @default.
- W4317863042 startingPage "TPS485" @default.
- W4317863042 abstract "TPS485 Background: Perioperative therapy, especially whether preoperative neoadjuvant therapy (NAT) can improve R0 resection rate and prolong overall survival of patients with locally advanced gastric cancer, has been paid more and more attention. NAT is mainly defined as a preoperative chemotherapy or chemoradiotherapy, aiming at increasing radical resection rate by downstaging tumor and eliminating micrometastases. Anlotinib is an oral multi-targeted tyrosine kinase inhibitor targeting VEGFR1/2/3, FGFR1-4 and PDGFRα/β, which effectively blocks tumor neovascularization and growth. Previous phase I/II clinical trials suggested that penpulimab monotherapy as second-line therapy was well tolerated and showed clinical anti-tumor activity in gastric or gastroesophageal junction carcinoma (GC/GEJ) (NCT03352531, NCT04172506). It was demonstrated an objective response rate (ORR) of 26.3%, a disease control rate (DCR) of 42.1% in GC/GEJ patients (pts) using penpulimab monotherapy. This trial was designed to assess the feasibility and efficacy of penpulimab plus anlotinib combined with chemotherapy in perioperative treatment of pts with locally advanced gastric cancer. Methods: This is a multi-center, prospective, single-arm, phase II study. Resectable GC pts with TNM stage T3~4N+M0 per AJCC 8th , ECOG PS 0-1, were enrolled and treated with 3 cycles of preoperative penpulimab (200mg, iv, d1, q3w) + anlotinib (12mg, qd, d1-d14, q3w)+ SOX (oxaliplatin 130mg/m 2 , iv, d1 and S-1 40-60mg, po, bid, d1-14, q3w), and 12 months of postoperative adjuvant therapy formulated by investigators according to the individual situation of the pts. Primary endpoint was pathological complete response (pCR) rate. Secondary endpoints included major pathologic response (MPR) rate, disease free survival (DFS), objective response rate (ORR), R0 resection rate and safety. Based on a two-sided test for one proportion with 5.0% type I error, 80% power to detect an improvement in the rate of pCR from 13% to 29%, there will be 57 pts enrolled considering 10% of pts dropping out. Clinical trial information: NCT05385900 ." @default.
- W4317863042 created "2023-01-25" @default.
- W4317863042 creator A5023333504 @default.
- W4317863042 creator A5063055791 @default.
- W4317863042 creator A5065598852 @default.
- W4317863042 creator A5083061945 @default.
- W4317863042 creator A5090954943 @default.
- W4317863042 creator A5061291408 @default.
- W4317863042 date "2023-02-01" @default.
- W4317863042 modified "2023-10-06" @default.
- W4317863042 title "Perioperative penpulimab plus anlotinib combined with chemotherapy for locally advanced gastric cancer: A single arm, multicenter, phase II clinical trial." @default.
- W4317863042 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.tps485" @default.
- W4317863042 hasPublicationYear "2023" @default.
- W4317863042 type Work @default.
- W4317863042 citedByCount "0" @default.
- W4317863042 crossrefType "journal-article" @default.
- W4317863042 hasAuthorship W4317863042A5023333504 @default.
- W4317863042 hasAuthorship W4317863042A5061291408 @default.
- W4317863042 hasAuthorship W4317863042A5063055791 @default.
- W4317863042 hasAuthorship W4317863042A5065598852 @default.
- W4317863042 hasAuthorship W4317863042A5083061945 @default.
- W4317863042 hasAuthorship W4317863042A5090954943 @default.
- W4317863042 hasConcept C121608353 @default.
- W4317863042 hasConcept C126322002 @default.
- W4317863042 hasConcept C141071460 @default.
- W4317863042 hasConcept C143998085 @default.
- W4317863042 hasConcept C203092338 @default.
- W4317863042 hasConcept C2776694085 @default.
- W4317863042 hasConcept C2777299880 @default.
- W4317863042 hasConcept C2779984678 @default.
- W4317863042 hasConcept C2780962732 @default.
- W4317863042 hasConcept C31174226 @default.
- W4317863042 hasConcept C31760486 @default.
- W4317863042 hasConcept C526805850 @default.
- W4317863042 hasConcept C535046627 @default.
- W4317863042 hasConcept C71924100 @default.
- W4317863042 hasConceptScore W4317863042C121608353 @default.
- W4317863042 hasConceptScore W4317863042C126322002 @default.
- W4317863042 hasConceptScore W4317863042C141071460 @default.
- W4317863042 hasConceptScore W4317863042C143998085 @default.
- W4317863042 hasConceptScore W4317863042C203092338 @default.
- W4317863042 hasConceptScore W4317863042C2776694085 @default.
- W4317863042 hasConceptScore W4317863042C2777299880 @default.
- W4317863042 hasConceptScore W4317863042C2779984678 @default.
- W4317863042 hasConceptScore W4317863042C2780962732 @default.
- W4317863042 hasConceptScore W4317863042C31174226 @default.
- W4317863042 hasConceptScore W4317863042C31760486 @default.
- W4317863042 hasConceptScore W4317863042C526805850 @default.
- W4317863042 hasConceptScore W4317863042C535046627 @default.
- W4317863042 hasConceptScore W4317863042C71924100 @default.
- W4317863042 hasIssue "4_suppl" @default.
- W4317863042 hasLocation W43178630421 @default.
- W4317863042 hasOpenAccess W4317863042 @default.
- W4317863042 hasPrimaryLocation W43178630421 @default.
- W4317863042 hasRelatedWork W2152161571 @default.
- W4317863042 hasRelatedWork W2169598597 @default.
- W4317863042 hasRelatedWork W2234542209 @default.
- W4317863042 hasRelatedWork W2589344854 @default.
- W4317863042 hasRelatedWork W2999356969 @default.
- W4317863042 hasRelatedWork W3118214896 @default.
- W4317863042 hasRelatedWork W3208353204 @default.
- W4317863042 hasRelatedWork W4229045579 @default.
- W4317863042 hasRelatedWork W4281680475 @default.
- W4317863042 hasRelatedWork W4318903887 @default.
- W4317863042 hasVolume "41" @default.
- W4317863042 isParatext "false" @default.
- W4317863042 isRetracted "false" @default.
- W4317863042 workType "article" @default.